Biocon’s arm inks pact to acquire Viatris’ biosimilars business

28 Feb 2022 Evaluate

Biocon’s subsidiary -- Biocon Biologics (BBL) has entered into a definitive agreement with its partner Viatris Inc. Accordingly, BBL will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to $3.335 billion, including cash up to $2.335 billion and Compulsorily Convertible Preference Shares (CCPS) in BBL, valued at $1 billion.

BBL will have a comprehensive portfolio comprising its current range of commercialized insulins, oncology and immunology biosimilars as well as several other biosimilar assets currently under development. BBL also has access to the vaccines portfolio through its previously announced partnership with Serum Institute Life Sciences (SILS).

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

379.50 -0.75 (-0.20%)
17-Feb-2026 12:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.35
Dr. Reddys Lab 1269.85
Cipla 1346.30
Zydus Lifesciences 907.45
Lupin 2248.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×